The European Medicines Agency's review of Kaftrio (elexacaftor-tezacaftor-ivacaftor): extending its use to all people with CF aged 2 years and older who do not have two class I CFTR variants.

IF 21 1区医学 Q1 RESPIRATORY SYSTEM

European Respiratory Journal Pub Date : 2025-10-09 DOI:10.1183/13993003.01506-2025

Catherine Drai,Hanneke J van der Woude,Anne J Lexmond,Tineke van den Hoorn,Peter G M Mol,Finbarr P Leacy,Agnieszka Przybyszewska,Bruno Sepodes,Thomas Castelnovo

引用次数: 0

查看原文本刊更多论文

欧洲药品管理局（ema）对Kaftrio （elexacaftor-tezacaftor-ivacaftor）的审查：将其应用范围扩大到所有2岁及以上且没有两种I类CFTR变体的CF患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Respiratory Journal 医学-呼吸系统

CiteScore

27.50

自引率

3.30%

发文量

345

审稿时长

2-4 weeks

期刊介绍： The European Respiratory Journal (ERJ) is the flagship journal of the European Respiratory Society. It has a current impact factor of 24.9. The journal covers various aspects of adult and paediatric respiratory medicine, including cell biology, epidemiology, immunology, oncology, pathophysiology, imaging, occupational medicine, intensive care, sleep medicine, and thoracic surgery. In addition to original research material, the ERJ publishes editorial commentaries, reviews, short research letters, and correspondence to the editor. The articles are published continuously and collected into 12 monthly issues in two volumes per year.